# AstraZeneca

> AstraZeneca is a VC fund in Cambridge backing Health Care and Biotechnology. See 51 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United Kingdom
- Total investments: 51
- Last investment: Nov 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/astrazeneca
- X (Twitter): http://twitter.com/astrazeneca
- Website: http://www.astrazeneca.com
- Facebook: https://www.facebook.com/astrazenecacareers

AstraZeneca is a VC fund in Cambridge focused on Health Care and Biotechnology. AstraZeneca is global innovation-driven biopharmaceutical company specializing in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicineswhich are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. AstraZeneca focus on getting the best from every medicine they make by exploring all the ways it can be used or improved.

## Contacts

5 contacts available for AstraZeneca. Shizune tracks 10 team members at AstraZeneca. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/astrazeneca?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 24 | 47% |
| Biotechnology | 19 | 37% |
| Medical | 14 | 27% |
| Non Profit | 9 | 18% |
| Therapeutics | 8 | 16% |

36 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Grant | 17 | 33% |
| Series A | 6 | 12% |
| Series D | 4 | 8% |
| Post-IPO Equity | 4 | 8% |
| Seed | 3 | 6% |

14 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 25 | 49% |
| China | 4 | 8% |
| France | 2 | 4% |
| Israel | 2 | 4% |
| Sweden | 2 | 4% |

11 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Bonnie Cheuk | Senior Business and Digital Transformation Leader | 0 | — |
| Bruce Burlington | Non-Executive Director | 0 | — |
| Carl Sidenvall | Project Manager | 0 | — |
| Katarina Ageborg | Chief Compliance Officer | 0 | — |
| Nicholas Darton | Principal Scientist | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cassidy Bio | A biotechnology company developing AI-driven genomic foundation models | $8M | Seed | Nov 20, 2025 |  |
| Sortera Bio | Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M | Pre-Seed | Jun 05, 2025 |  |
| Harbour Biomed | Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager(HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development. | $105M | Post-IPO Equity | Mar 21, 2025 |  |
| Promise Bio | Promise Bio develops a virtual AI platform that helps to identify multiple Post-Translational Modifications in proteins from a single blood sample. It helps to cure chronic diseases. | $8.3M | Seed | Oct 23, 2024 |  |
| Huma | Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research.The company was founded in 2011 and is headquartered inLondon, England. | $80M | Series D | Jul 16, 2024 |  |
| SmartCella | SmartCella is an innovative biotechnology and medtech company. Sweden. SmartCella’s therapeutic mission is to develop treatments for patients running out of options. The company has three main business units, Procella Therapeutics, Smartwise and SvedMed Solutions. | $54.2M | Private Equity | Jul 08, 2024 |  |
| Nucleus RadioPharma | Nucleus RadioPharma is a new company that was founded to ensure that cancer patients have access to potentially life-saving radiopharmaceuticals by developing technologies to modernise the clinical development, manufacturing, and supply chain of these promising new therapies. |  | Series A | Jun 05, 2024 |  |
| SixPeaks Bio | SixPeaks is developing a pipeline of medicines for healthy weight loss. | $30M | Series A | May 22, 2024 |  |
| SixPeaks Bio | SixPeaks is developing a pipeline of medicines for healthy weight loss. | $80M | Debt Financing | May 22, 2024 |  |
| Asher Bio | Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer. The company was founded in 2019 and headquartered in San Francisco, California. | $55M | Series C | Apr 16, 2024 |  |

10 of 51 investments shown.

## Co-investors
- [HSG](https://shizune.co/investors/profile/hsg-cap) — VC Fund, 3 deals together
- [HSG](https://shizune.co/investors/profile/sequoia-capital-china) — VC Fund, 3 deals together
- Auven Therapeutics — VC Fund, 2 deals together
- [Awz Ventures](https://shizune.co/investors/profile/awz-ventures-2) — VC Fund, 2 deals together
- [CICC](https://shizune.co/investors/profile/cicc) — VC Fund, 2 deals together
- [Fletcher Spaght, Inc.](https://shizune.co/investors/profile/fletcher-spaght-inc) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund
- [Foundation for Innovation and Technology (FIT)](https://shizune.co/investors/profile/foundation-pour-l-innovation-technologique) — VC Fund
- [Business Finland](https://shizune.co/investors/profile/tekes) — VC Fund

## FAQ

### What does AstraZeneca invest in?

AstraZeneca invests primarily in Health Care, Biotechnology and Medical startups, most often at Grant and Series A stage. Most of the 51 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact AstraZeneca?

Public channels for AstraZeneca include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at AstraZeneca?

The team at AstraZeneca includes Bonnie Cheuk (Senior Business and Digital Transformation Leader), Bruce Burlington (Non-Executive Director) and Carl Sidenvall (Project Manager), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co